Drug Trial Radar · NCT01696058
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
Last checked: Nov 19, 2026Latest source record: Nov 25, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,137
Actual
Start
Sep 2012
Primary completion
Oct 2013
Study completion Oct 2013
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Sep 28, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The overall objective of this study is to assess efficacy and safety of 12 weeks, once daily, orally inhaled co-administration of olodaterol 5 µg (delivered by the Respimat® Inhaler) and tiotropium (delivered by the Handihaler® as Spiriva Handihaler®), compared to tiotropium (Spiriva Handihaler®) monotherapy on lung function in patients with COPD.
Conditions
- Pulmonary Disease, Chronic Obstructive
Interventions
TiotropiumDrug
marketed product
Placebo matching OlodaterolDrug
one dose
TiotropiumDrug
marketed product
OlodaterolDrug
one dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- FEV1 AUC0-3h Response at 12 Weeks; Defined as Change From Baseline to Week 12Time frame: baseline and 12 weeks
- Trough FEV1 Response at 12 Weeks; Defined as Change From Baseline to Week 12Time frame: baseline and 12 weeks
Locations
94 sites in 1 country. Site status is shown where the registry gives one.
1222.52.02090 Boehringer Ingelheim Investigational Site
Anniston, Alabama
1222.52.02046 Boehringer Ingelheim Investigational Site
Birmingham, Alabama
1222.52.02014 Boehringer Ingelheim Investigational Site
Mobile, Alabama
1222.52.02017 Boehringer Ingelheim Investigational Site
Montgomery, Alabama
1222.52.02092 Boehringer Ingelheim Investigational Site
Anchorage, Alaska
1222.52.02072 Boehringer Ingelheim Investigational Site
Chandler, Arizona
1222.52.02063 Boehringer Ingelheim Investigational Site
Glendale, Arizona
1222.52.02088 Boehringer Ingelheim Investigational Site
Peoria, Arizona
1222.52.02012 Boehringer Ingelheim Investigational Site
Phoenix, Arizona
1222.52.02006 Boehringer Ingelheim Investigational Site
Huntington Beach, California
1222.52.02031 Boehringer Ingelheim Investigational Site
San Jose, California
1222.52.02011 Boehringer Ingelheim Investigational Site
Torrance, California
1222.52.02061 Boehringer Ingelheim Investigational Site
Boulder, Colorado
1222.52.02054 Boehringer Ingelheim Investigational Site
Fort Collins, Colorado
1222.52.02001 Boehringer Ingelheim Investigational Site
Hartford, Connecticut
1222.52.02037 Boehringer Ingelheim Investigational Site
Norwalk, Connecticut
1222.52.02055 Boehringer Ingelheim Investigational Site
Waterbury, Connecticut
1222.52.02094 Boehringer Ingelheim Investigational Site
Clearwater, Florida
1222.52.02022 Boehringer Ingelheim Investigational Site
Fort Lauderdale, Florida
1222.52.02074 Boehringer Ingelheim Investigational Site
Orlando, Florida
1222.52.02016 Boehringer Ingelheim Investigational Site
Ponte Verda, Florida
1222.52.02084 Boehringer Ingelheim Investigational Site
Saint Petersberg, Florida
1222.52.02043 Boehringer Ingelheim Investigational Site
Tampa, Florida
1222.52.02009 Boehringer Ingelheim Investigational Site
Blue Ridge, Georgia
1222.52.02048 Boehringer Ingelheim Investigational Site
Duluth, Georgia
1222.52.02077 Boehringer Ingelheim Investigational Site
Gainsville, Georgia
1222.52.02040 Boehringer Ingelheim Investigational Site
Rincon, Georgia
1222.52.02024 Boehringer Ingelheim Investigational Site
O'Fallon, Illinois
1222.52.02002 Boehringer Ingelheim Investigational Site
Muncie, Indiana
1222.52.02008 Boehringer Ingelheim Investigational Site
Fort Mitchell, Kentucky
1222.52.02025 Boehringer Ingelheim Investigational Site
Louisville, Kentucky
1222.52.02089 Boehringer Ingelheim Investigational Site
New Orleans, Louisiana
1222.52.02005 Boehringer Ingelheim Investigational Site
Baltimore, Maryland
1222.52.02029 Boehringer Ingelheim Investigational Site
Columbia, Maryland
1222.52.02036 Boehringer Ingelheim Investigational Site
Hollywood, Maryland
1222.52.02015 Boehringer Ingelheim Investigational Site
Townson, Maryland
1222.52.02034 Boehringer Ingelheim Investigational Site
North Dartmouth, Massachusetts
1222.52.02003 Boehringer Ingelheim Investigational Site
Chelsea, Michigan
1222.52.02020 Boehringer Ingelheim Investigational Site
Kalamazoo, Michigan
1222.52.02047 Boehringer Ingelheim Investigational Site
Minneapolis, Minnesota
Showing 40 of 94 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.